SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a report that the company is preparing a potential takeover bid for eBay, fueling intense debate among investors regarding the feasibility of such a large-scale acquisition. Community members are actively split between those anticipating a major catalyst for a short squeeze and skeptics questioning the financial mechanics and strategic logic behind combining the two legacy retailers.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently trending due to a surge in community discussion surrounding its potential for quantum-resistant utility and recent institutional attention, fueling speculation about a possible breakout. While some investors are actively accumulating the coin at lower levels, others remain skeptical, leading to a polarizing debate between those expecting a significant price squeeze and those predicting further downside.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports that GameStop is potentially preparing an acquisition bid for the e-commerce giant, sparking intense debate among the community regarding the feasibility of such a large-scale deal. Retail investors and market commentators are actively questioning how GameStop would finance the acquisition while debating the strategic logic of combining these legacy brands.

Veil Cash is a privacy application leveraging zk-SNARKs on Base L2, enabling verified depositors to achieve privacy and anonymity within a pool of trusted users.  Veil Cash is a non-custodial privacy protocol on Base L2. Veil Cash's goal will be enabling verified users to achieve privacy and anonymity from trusted pools.  Veil is a set of smart contracts that will allow users that are deemed as verified users to deposit into the protocol. Users can later withdraw their deposits from another address without creating a link between these two addresses.   Verified users are those who meet certain criteria based on both on-chain and off-chain data.

Veil-project

VEIL is trending as community members rally behind its focus on privacy technology and decentralized network security. Investors are actively discussing the project's potential within the Base ecosystem and the growing interest in privacy-focused assets.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is experiencing high trading activity as investors react to the company's recent BLA submission for its lead drug candidate, ivonescimab, and its new clinical trial collaboration with GSK. The community is focused on the potential for this drug to disrupt the lung cancer treatment market, with active discussions centering on the upcoming interim progression-free survival data and the significance of the BLA filing ahead of a major industry conference.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is trending as investors digest a series of positive analyst initiations and technical partnerships, while the community focuses on its long-term potential in AI consulting and quantum computing. Despite recent price volatility, many market participants view the stock as undervalued and are tracking its momentum ahead of upcoming earnings.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls (RLS) is seeing increased community interest and volatility surrounding its recent mainnet launch and the activation of new tokenomics, including a transaction fee burn mechanism. While some investors are optimistic about potential institutional partnerships and long-term utility, others are debating whether current price movements indicate a genuine breakout or a speculative cycle.

WorldFinancial

WorldFinancial is currently under intense community scrutiny as traders debate the impact of proposed governance votes, including potential massive token burns and long-term vesting lockups. Sentiment remains deeply divided between those viewing the project as a speculative play on political connections and critics labeling it a highly manipulated asset plagued by controversy and governance concerns.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is currently a central focus for traders as they monitor a mix of institutional sentiment and high-energy community activity around memecoins like UPDOG and other project launches. Investors are actively discussing the potential for a breakout, with many tracking how current market conditions, including staking yields and broader crypto adoption trends, will influence its next major move.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently driven by heightened investor interest in its lead drug candidate, soquelitinib, as community discussions focus on its potential as a first-in-class oral treatment for atopic dermatitis and other inflammatory indications. Investors are closely monitoring upcoming clinical data readouts and institutional analyst activity, while the stock experiences significant volatility fueled by high short interest and speculative chatter regarding potential M&A activity.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nautilus Biotechnology Q1 Earnings Call Highlights

Nautilus Biotechnology (NASDAQ:NAUT) reported first-quarter 2026 results and highlighted progress toward its planned commercialization timeline, with management emphasizing expanding early customer...

Nautilus Biotechnology (NASDAQ:NAUT) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.12) earnings per share for the quarter, beating the consensus...

Nautilus Biotechnology Reports Q1 2026 Results: Full Earnings Call Transcript

Sentinel Trust Co. LBA Purchases New Position in Nautilus Biotechnology, Inc. $NAUT

Sentinel Trust Co. LBA purchased a new stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 750,000 shares of the company's stock, valued at approxi...

Nautilus Biotechnology (NAUT) Expected to Announce Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) will be releasing its Q1 2026 earnings before the market opens on Tuesday, April 28. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-28-nautilus-biotechnology-inc-stock...

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Sees Significant Increase in Short Interest

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 674,952 shares, an increase of 51.1% from the March 15th total of 446,652 shares. Approximately 0.9% of...

Nautilus Biotechnology Unveils Voyager Proteomics Platform, Targets Beta Access in 2H and Launch Next Year

Nautilus Biotechnology (NASDAQ:NAUT) executives outlined the company's strategy to unlock the power of the proteome and argued that better protein measurement tools could improve drug development...

Nautilus Biotechnology (NASDAQ:NAUT) Sets New 52-Week High - What's Next?

Nautilus Biotechnology (NASDAQ:NAUT) Reaches New 12-Month High - Time to Buy...

Sujal Patel Buys 25,000 Shares of Nautilus Biotechnology (NASDAQ:NAUT) Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CEO Sujal Patel bought 25,000 shares of the firm's stock in a transaction on Wednesday, March 4th. The shares were acquired at an average...

Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim

Guggenheim upped their target price on Nautilus Biotechnology from $2.50 to $4.00 and gave the stock a "buy" rating in a report on Friday...

Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal M. Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

NAUT
Nautilus Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NAUT News

NAUTNautilus Biotechnology Inc